Tirzepatide Cuts Cardiovascular Risk in HFpEF Patients with Obesity

Tirzepatide查看药品详情 (Eli Lilly查看公司主页) significantly reduced the risk of cardiovascular mortality and worsening heart failure (搜索)搜索该疾病 events by nearly 40% in patients with obesity and heart failure with preserved ejection fraction (HFpEF (搜索)搜索该疾病) over a median follow-up of roughly 2 years, according to results from the SUMMIT trial presented at the American Heart Association (AHA) 2024 Scientific Sessions.

The treatment benefit was primarily driven by a significant reduction in the risk of worsening HF events requiring hospitalization or urgent intravenous medication, with benefits emerging after 3 to 4 months. Milton Packer, MD (Baylor University Medical Center), emphasized the growing epidemic of obesity and its serious cardiovascular complication, HFpEF (搜索)搜索该疾病.

Impact on HFpEF Treatment

The SUMMIT trial included 731 patients with a mean age of 65.2 years and a mean BMI of 38 kg/m2. Nearly half of the patients had experienced HF decompensation within the previous 12 months, and high-sensitivity C-reactive protein (hs-CRP) levels were significantly elevated. Patients were randomized to receive either tirzepatide查看药品详情 or a placebo for up to 3 years.

Tirzepatide查看药品详情, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 agonist, is already approved for chronic weight management and type 2 diabetes. The study's findings suggest a potential expansion of its therapeutic role in cardiology.

Key Findings from SUMMIT

The primary endpoint, a composite of deaths from cardiovascular causes or worsening HF events, occurred in 9.9% of patients in the tirzepatide查看药品详情 group compared to 15.3% in the placebo group (HR 0.62; 95% CI 0.41-0.95). Hospitalizations for HF alone were significantly lower in the tirzepatide arm (3.3%) versus the placebo arm (7.1%), with a hazard ratio of 0.44 (95% CI 0.22-0.87).

There was also a significant improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score, with a between-group difference of 6.9 points at 52 weeks favoring tirzepatide查看药品详情 (P < 0.001). Additionally, tirzepatide led to an 18-m placebo-corrected improvement in the 6-minute walk distance and a significant 13.9% reduction in body weight compared to a 2.2% reduction in the placebo group (P < 0.001).

Expert Commentary

Sanjiv Shah, MD (Northwestern Feinberg School of Medicine), noted that the SUMMIT trial reinforces the benefits observed with semaglutide查看药品详情 in previous STEP-HFpEF (搜索)搜索该疾病 trials, solidifying the role of these drugs in HFpEF treatment. Jennifer Ho, MD (Beth Israel Deaconess Medical Center), described SUMMIT as a "practice-changing trial," emphasizing its potential to affect the management of the majority of HFpEF patients who have obesity or are overweight.

Robert Mentz, MD (Duke University School of Medicine), highlighted that SUMMIT provides data showing a benefit in terms of HF hospitalizations beyond the improvement in symptoms and function seen in STEP-HFpEF (搜索)搜索该疾病. He cautioned, however, that the relatively modest number of events in the trial should be kept in context.

Challenges and Future Directions

Despite the promising results, challenges remain in ensuring patient access to these medications. Ho noted that GLP-1 receptor agonist discontinuation is a significant problem, with many patients stopping the medication within a year. Packer emphasized that patients need to stay on the medication to maintain its benefits, while Shah called for healthcare community advocacy to reduce prices and improve coverage for these drugs.

Further research is needed to address the residual risk in HFpEF (搜索)搜索该疾病 patients and to explore alternative mechanisms for improving outcomes. Studies from STEP-HFpEF and SUMMIT suggest that weight loss is a major mechanism of benefit, but other factors may also be involved.